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Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a long-term complication following an
acute pulmonary embolism (PE). It is frequently diagnosed at advanced stages which is concerning as delayed
treatment has important implications for favourable clinical outcome. Performing a follow-up examination of
patients diagnosed with acute PE regardless of persisting symptoms and using all available technical procedures
would be both cost-intensive and possibly ineffective. Focusing diagnostic procedures therefore on only symptomatic
patients may be a practical approach for detecting relevant CTEPH.
This study aimed to evaluate if a follow-up program for patients with acute PE based on telephone monitoring of
symptoms and further examination of only symptomatic patients could detect CTEPH. In addition, we investigated the
role of cardiopulmonary exercise testing (CPET) as a diagnostic tool.
Methods: In a prospective cohort study all consecutive patients with newly diagnosed PE (n=170, 76 males, 94 females
within 26 months) were recruited according to the inclusion and exclusion criteria. Patients were contacted via
telephone and asked to answer standardized questions relating to symptoms. At the time of the final analysis 130
patients had been contacted. Symptomatic patients underwent a structured evaluation with echocardiography, CPET
and complete work-up for CTEPH.
Results: 37.7%, 25.5% and 29.3% of the patients reported symptoms after three, six, and twelve months respectively.
Subsequent clinical evaluation of these symptomatic patients saw 20.4%, 11.5% and 18.8% of patients at the respective
three, six and twelve months time points having an echocardiography suggesting pulmonary hypertension (PH).
CTEPH with pathological imaging and a mean pulmonary artery pressure (mPAP) ≥ 25 mm Hg at rest was
confirmed in eight subjects. Three subjects with mismatch perfusion defects showed an exercise induced
increase of PAP without increasing pulmonary artery occlusion pressure (PAOP). Two subjects with pulmonary
hypertension at rest and one with an exercise induced increase of mPAP with normal PAOP showed perfusion
defects without echocardiographic signs of PH but a suspicious CPET.
Conclusion: A follow-up program based on telephone monitoring of symptoms and further structured evaluation
of symptomatic subjects can detect patients with CTEPH. CPET may serve as a complementary diagnostic tool.
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The incidence of chronic thromboembolic pulmonary
hypertension (CTEPH) after an acute pulmonary embo-
lism (PE) varies between 0.5 – 8% depending on the
study population [1-4]. Inclusion of patients with un-
provoked PE [4] and subjects with a history of previous
pulmonary embolism results in a cohort with a higher
incidence of CTEPH [5]. Exclusion of patients with co-
morbidities could lead to a lower incidence rate. There
is still an ongoing debate about the true incidence of
CTEPH. It is critical to note that patients are frequently
diagnosed with CTEPH at advanced stages of the disease
leading to worse clinical outcomes which could theore-
tically be alleviated through earlier treatment [6,7]. Regis-
try data show that the majority of patients undergoing
pulmonary thrombendarterectomy (PEA) are at WHO
functional class III [8]. Recent data suggests that on aver-
age an 18 to 24 months delay exists from onset of symp-
toms to the final diagnosis of CTEPH [9]. Although
modern management of CTEPH including PEA in ope-
rable patients and the use of targeted therapies improved
survival [6,8], CTEPH is still a disease with a serious
prognosis [6]. Since outcome remains poor in non-
treated patients [10,11] and is dependent of WHO func-
tional class [7,8], late detection of CTEPH might lead to
an even worse prognosis. Among patients who under-
went PEA in-hospital survival as well as 1-year-survival
was associated with the time elapsed between the last
pulmonary embolism and PEA [8]. Recent data suggests
that patients with perfusion abnormalities and a border-
line PH at rest, but an increase under exercise without an
increase of pulmonary arterial occlusion pressure
improve following an early pulmonary thrombendar-
terctomy [9]. Overall, evidence from various sources sug-
gests that early detection and treatment of CTEPH is
advantageous in achieving favourable clinical outcomes.
Incomplete thrombus resolution after pulmonary
embolism is not a rare finding [12]. Given the incidence
of pulmonary embolism of 0.6 -1.45/1000 person-years
[13-15], a high rate of undiagnosed CTEPH is very likely.
Symptoms of pulmonary hypertension are unspecific
[16]. This might contribute to a still existing delay from
onset of symptoms to diagnosis of CTEPH [9], especially
in elderly patients.
Although Echocardiography is currently used as a
method to detect elevated systolic right ventricular pres-
sure, it has been associated with false negative results
and may not always detect pulmonary hypertension.
[17-22]. Cardiopulmonary exercise testing can help to
distinguish CTEPH from PAH [23] and has been
suggested as a reliable method to detect CTEPH when
echocardiography results are negative [17]. This suggests
that it could be a helpful tool for early diagnosis of
CTEPH.Incomplete thrombus resolution after acute pul-
monary embolism without clinical symptoms has
been reported [24,25]. It would be interesting to see
quantitative and qualitative data on asymptomatic
subjects with pathological VQ-scan and incomplete
thrombus resolution developing CTEPH. However,
complete follow-up examination using all technical
procedures available in all patients at the first step,
such as echocardiography, CT-scan, V/Q scan of all
patients with acute PE could be cost-intensive and
ineffective in detecting CTEPH. Focusing further
structured diagnostic evaluation on symptomatic
patients only may therefore be an ethical and effec-
tive approach and a concept in detecting relevant
CTEPH.
Objective
As there are currently no established structured follow-
up programs for early detection of CTEPH, this study
aimed to evaluate a novel follow-up program based on a
telephone monitoring of patient reported symptoms and
consecutive step by step evaluation for patients with pul-
monary embolism to detect CTEPH. Furthermore this
study evaluated cardiopulmonary exercise testing (CPET)
as a complementary diagnostic tool for early detection of
CTEPH.
Methods
The study design is summarized in Figure 1. In an on-
going observational program, we prospectively studied
all consecutive patients, who presented with newly diag-
nosed PE at the Medical Mission Hospital from January
2011 to February 2013. We did not exclude any patients
with comorbidities or a history of previous pulmonary
embolism. After written informed consent was obtained
we included patients with idiopathic as well as patients
with provoked pulmonary embolism. Patients at least
18 years old were included and were contacted after
three, six, twelve, 24 and 36 months by a standardized
telephone call in which they were interviewed according
to a questionnaire for the following symptoms: dyspnea
at rest, dyspnea on exertion, dizziness, fainting or syncope
or thoracic pain. The online Additional files 1 and 2:
Figure S1-S2 detail this questionnaire. If any item of a
five item-questionnaire was reported as positive patients
were invited for an outpatient visit including an echo-
cardiography. Echocardiography (Vivid7®, GE Medical Sys-
tems, Solingen, Germany) was performed according to the
guidelines [19,26-28]. If the echocardiography suggested nor-
mal results, a CPET was performed. An echocardiography or
a CPET indicative of PH warranted further evaluation.
CPET (Masterscreen CPX®, CareFusion, Hoechberg,
Germany; E-bike basic PC plus, GE Medical Systems,
Solingen, Germany) was performed according to the
Figure 1 Study design.
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Statement as recently described including a two-minute
registration at rest and two-minute recording of unloaded
pedaling [29,30]. The following exercise protocol consisted
of an increasing work load of 25 Watt /2 min per ramp.
We terminated exercise by symptom limitation or when
withdrawal criteria were met. Respiratory rate and mi-
nute ventilation as well as expiratory fraction of O2 and
CO2 were measured breath by breath. Temperature and
air pressure were recorded continuously. Anaerobic
threshold was determined at EQO2 nadir. The following
parameters were assumed as indicative for disturbed
pulmonary perfusion and leading to a recommendation
for a complete diagnostic work-up: EQO2 > 25, EQ
CO2 > 35, VE/VCO2 > 35, PET CO2 < 35 mmHg or
decreasing during exercise, PaETCO2 > 0 mmHg at
maximum load, and/or P(A-a)O2 > 35 mm Hg at the
peak exercise.
Further evaluation was conducted as described above
if either the echocardiography showed signs of pulmon-
ary hypertension, or if echocardiography was normal
and CPET was suggestive of pulmonary perfusion abnor-
malities [17].
A complete diagnostic work-up according to the current
guidelines including imaging studies and right heart
catheterization was suggested as a procedure agreeing with
the standard care. CTEPH was assumed when mismatched
perfusion defects were detected by VQ scan (Technegas-
Generator®, Tetley Medical Limited, Australia; E Cam
Variable®, Siemens Medical Solutions Inc., Hoffman Estates,
Illinois, USA) or computed tomography scan (Activion 16®,
Toshiba Medical Systems, Neuss, Germany) showed filling
defects and right heart catheter revealed precapillarypulmonary hypertension [26,27]. Right heart catheterization
was performed according to the guidelines using a Swan
Ganz catheter (Smith Medical, Grasbrunn, Germany)
[26,31]. Measurements were conducted with the monitor
system IntelliVue MP70 (M8007A)®, Philips Medizinsys-
teme, Böblingen, Germany. For confirmation of CTEPH
and for the operability assessment a pulmonary angio-
graphy (Integris Allura; Philips Medical Systems, Best, The
Netherlands, films stored digitally) was performed as part
of standard care.
Operability was then evaluated by a multidisciplinary
team consisting of a respiratory physician, cardiologist,
radiologist and a surgeon specialized and highly experi-
enced in pulmonary thrombendarterectomy.
Written informed consent was obtained from all
patients prior to inclusion. The study was approved by
the local Ethics Committee of the Julius Maximilian
University of Würzburg and was performed according to
the Declaration of Helsinki.
Results
As this study is still recruiting patients and undergoing an
extensive follow-up program for patients with acute pul-
monary embolism the data collection is not yet finalized.
26 months after this program has started 130 patients
had passed a time point of three-months-follow-up, 102
patients had completed six-months follow-up and 58 pa-
tients had passed the point of twelve-months-follow up.
Table 1 shows the anthropometric baseline data of the
130 patients who had passed the 3-months follow-up
period. Table 2 shows the results of the telephone calls
and clinical data after visits at three, six and twelve
months.
Table 1 Anthropometric data and comorbidities at
baseline of the 130 patients who had been contacted at
3 months of follow-up, data is from the analysis on
February 28 th 2013
Baseline data n %
Patients contacted 130
Sex m/f 55/75 42.3%/57.7%
Mean +/−SD
Age (years) 65.7 17.0
Height (cm) 170 9.5
Weight (kg) 82.5 17.2
BMI (kg/m2) 28.6 5.4
Comorbidities n %
Arterial hypertension 55 42.3
Coronary artery disease 11 8.5
Atrial fibrillation/flutter 19 14.6
Heart valve pathology 8 6.2
COPD 10 7.7
Asthma 8 6.2
Interstitial lung disease 6 4.6
Sleep related breathing disorder 11 8.5
Alveolar hypoventilation 1 0.8
Diabetes 15 11.5
Chronic kidney disease 9 6.9
Liver disease 6 4.6
Thyroid disorder/Struma 25 19.2
Rheumatism/collagen vascular disease 7 5.4
Table 2 Results of telephone monitoring and administration
cardiopulmonary exercise testing and further evaluation con
Visit 1, 3 month
N(%)
Telephone calls 130
5-Item-Questionnaire positiv 49 (37.7%)
Outpatient visits 49
Echocardiography, n = 49
RVSP >/=35 mm Hg 10 (20.4%)
REVSP < 35 mm Hg/ not detectable 39 (79.6%)
Cardiopulmonary exercise testing, n = 34
Abnormal pulmonary perfusion suspected 12 (35.28%)
Further evaluation 21
CTEPH/CTPVD proven per visit 5(3.85)/2(1.5%)
CTEPH/CTPVD proven, all patients 5(3.85%)/2(1.5%)
26 months after the start of the program 130 patients had passed 3-months follow
passed twelve months-follow-up.
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of 130 patients who had completed the follow-up period
and had been contacted and interviewed via telephone
reported at least one symptom out of five outlined in the
questionnaire. In all 49 symptomatic patients an echo-
cardiography was performed. Echocardiography showed
a right ventricular systolic pressure (RVSP) of at least
35 mmHg in ten (20.4%) patients suggesting a positive
readout for PH. 39 patients (79.6%) saw negative results
from the echocardiography. 34 of these 39 subjects
underwent subsequent CPET. Of these 34 patients, 12
(35%) patients had CPET results suggesting CTEPH. In
total 21 patients of the 22 who had test results sugges-
ting CTEPH underwent a complete work-up for CTEPH.
In one patient with a VQ-scan suggesting CTEPH this
diagnosis was ruled out by pulmonary angiography. In
five subjects CTEPH was confirmed. In two subjects
chronic thromboembolic pulmonary vascular disease
(CTPVD) with an exercise induced PH (normal pulmonary
artery pressure at rest, but an exercise-induced increase of
mean pulmonary artery pressure (mPAP) without an
increase of pulmonary artery wedge pressure (PAWP) was
confirmed.
In four subjects with suspicion of PH a complete work-
up was recommended, but right heart catheterization was
delayed by the patients. Comorbidities of the 49 subjects
with reported symptoms were arterial hypertension (14/49),
malignancies (8/49), coronary artery disease (6/49), chronic
obstructive pulmonary disease (5/49), atrial fibrillation
(3/49), asthma (3/49), interstitial lung disease (3/49)
and cardiac valve pathology (1/49).
After six months 26 out of 102 (25.5%) patients who
had passed the six-month follow-up period wereof 5-item-questionnaire, echocardiography,
firming CTEPH
s Visit 2, 6 months Visit 3, 12 months
N(%) N(%)
102 58
26 (25.5%) 17 (29,3%)
26 17
n = 26 n = 16
3 (11.5%) 3 (18.8%)
23 (88.5%) 13 (81.25%)
n = 15 n = 9
4 (26.7%) 1 (11.1%)
7 4
3(2.94/1(0.98%) 0/0.0%)
8(6.2%)/3(2.3%) 8(6.2%)/3(2.3%)
-up, 102 patients had completed 6 months follow-up and 58 patients had
Table 3 Results from the analysis 27 months after the
start of the follow-up program: deaths, drop-outs and
cases with confirmed CTEPH are shown in relation to the
subjetcs who passed three-months follow-up
Results: 27 months analysis N %
Patients died 15 11.5%
Dropouts 4 3.0%
CTEPH/CTPVD with exercise PH* 8/3 6.2%/2.3%
CTEPH/CTPVD: “CPET pos and Echo neg“# 2/1 1.5/0.77%
*In 8 patients pathological imaging and mean pulmonary artery pressure
(mPAP) at rest of ≥ 25 mmHg had been found. In 3patients pathological
imaging, mPAP at rest of < 25 mmHg, but increasing mPAP under exercise
without increasing pulmonary artery occlusion pressure had been found
suggesting CTPVD with exercise induced PH. # 2 out of 8 (25%) patients
diagnosed with CTEPH and 1 out of 3 (33%) patients diagnosed with CTPVD
and exercise induced PH showed normal echocardiography, but findings in
the cardiopulmonary exercise test suspicious for functional relevant pulmonary
perfusion abnormalities.
Table 4 Haemodynamic data of eleven patients with
pathological imaging findings
mPAP at
rest >/=25 mm Hg
(n = 8)
mPAP at
rest < 25 mm Hg
(n = 3)
Mean SD Mean SD
mPAP (mmHg) 36 11 21 2
PAWP (mmHg) 10 3.8 9 3.6
PVR (dyn x sec x cm−5) 512 339 196 55
CO (l/min)* 4.5 1.2 4.77 1.0
CI (l/min/m2) 2.3 0.5 2.4 0.3
RAP (mmHg) 9 3 2.3 1.2
mPAP under exercise (mmHg) - 51 8
PAWP under exercise (mmHg) - 11 3.6
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described. RVSP was at least 35 mmHg in three patients
(11.5%) and normal in 23 patients (88.5%). Abnormal
pulmonary perfusion was suspected by CPET in 4 out of
15 (26.7%) patients. Following echocardiography testing
and CPET seven patients underwent a complete clinical
evaluation in which CTEPH was diagnosed in three
patients and CTPVD in one patient. These four patients
were symptomatic at the three months visit and a
complete work-up had been recommended at this time.
After twelve months 17 out of 58 (29.3%) patients who
had passed the 12-months-follow-up period reported
symptoms and were invited to participate in an
outpatient visit as described. Echocardiography was per-
formed in 16 subjects and revealed an RVSP of at least
35 mm Hg in three patients (18.8%). Echocardiography
was normal in 13 patients (81.2%). Of these subjects one
showed a CPET suggestive of a disturbed pulmonary
perfusion. However, CTEPH was not confirmed in any
further patient at visit 3 after 12 months.
Taken together, after the 26 months of interim
analysis, out of 130, 104 and 58 patients who had passed
the three, six- and twelve month follow-up period
respectively, in total eight patients were diagnosed with
CTEPH defined by a mean pulmonary artery pressure at
rest of ≥ 25 mm Hg and pathological imaging. One of
these patients had a pulmonary artery occlusion pressure
suggestive for additional diastolic left ventricular dys-
function. Three additional subjects with mismatched perfu-
sion defects detected by VQ scan showed an mPAP<
25 mm Hg at rest with an increase of mPAP while exercising
without an increasing pulmonary artery occlusion pressure.
Two subjects with precapilary pulmonary hypertension
at rest and one with an exercise induced increase of mPAP
with normal pulmonary arterial occlusion pressure showed
a pathological VQ scan without echocardiographic signs of
pulmonary hypertension but a cardiopulmonary exercise
test consistent with PH.
26 months after the start of the program 15 of the 130
contacted patients had died. There were four additional
drop-outs described in Table 3. Table 4 shows the
hemodynamic data of the eight patients with CTEPH
and 3 subjects with CTPVD. Statistics are described as
Mean ± SD. One patient presented with severe PH and
two patients showed moderate PH. The other subjects
had a mildly elevated pulmonary artery pressure at rest.
Out of eleven subjects with CTEPH or CTEPV one was
not suitable for surgery due to peripheral localization of
the thromboembolic lesions. For three of the remaining
ten subjects surgery was not recommended after careful
consideration of the potential benefit risk ratio taking into
account age, comorbidities and relatively slight hemao-
dynamic impairment. Overall seven patients were suitable
for a pulmonary thrombendarterectomy.Discussion
To the best of our knowledge there is no established
telephone based monitoring follow-up program for
CTEPH following PE. Here we show that a symptom-
related telephone-monitoring based approach with
consecutive diagnostic work-up of symptomatic subjects
can detect CTEPH in patients after pulmonary embolism.
PE patients were included in the study regardless of co-
morbidities such as malignancies or a possible history of
previous PE. This leads to a cohort with a CTEPH inci-
dence of 6.2% and of 2.3% of patients with exercise in-
duced PH and pathological imaging findings respectively.
Previously, the latter condition was described as chronic
thromboembolic pulmonary vascular disease [9,17]. The
CTEPH detection rate is slightly higher than reported in
other studies [1,3,4]. We cannot exclude that some of the
subjects with detected CTEPH had an acute on chronic
PE at the time of inclusion. The study, however, was not
designed to find the true incidence of CTEPH, but rather
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CTEPH early after pulmonary embolism.
The drop-out rate of this study to date has been low
and a mortality rate of 11.5% was observed during
follow-up. This value is not any higher than what was
expected and is comparable to previous reports on co-
horts of patients after acute pulmonary embolism [3,4].
The high percentage of symptomatic patients at three,
six and twelve month’s follow-up is likely due to the fact
that symptoms of CTEPH such as dyspnea and thoracic
pain are not specific. For instance especially in an older
population, left heart disease and COPD can also lead to
dyspnea. The comorbidities reported in our study in-
cluded airway diseases as well as arterial hypertension,
coronary artery disease and atrial fibrillation. Together,
these comorbidities represent the typical of a cohort of
patients with the presented age and inclusion criteria.
The data acquired in this study suggests that telephone-
monitoring can detect symptoms and subsequent exami-
nation of symptomatic subjects can be used to facilitate an
early diagnosis of CTEPH. The questionnaire based ap-
proach however remains unspecific and does not substitute
the skills of an experienced physician. As only symptomatic
patients were clinically evaluated for CTEPH, we cannot
exclude missing the diagnosis CTEPH in an individual
asymptomatic patient. Overall, the CTEPH rate is slightly
higher than that reported in research from other groups [3].
Focusing only on symptomatic patients seems to be a
pragmatic approach for detecting CTEPH. This is
because a follow-up program using all available diagnos-
tic tools and techniques for detection of CTEPH after
PE would be expensive and may not be cost-effective as
persisting perfusion defects due to incomplete thrombus
resolution without hemodynamical abnormalities has
been described [24,25].
Furthermore, as two out of eight patients with diagnosed
CTEPH and one out of three subjects with pathological
VQ scan and exercise induced PH had a normal echocar-
diography but CPET pattern suggestive of CTEPH, it can
be suggested that CPET may be a helpful complementary
tool for the diagnosis of CTEPH. These results are in ac-
cord with recent data which also suggests CPET as a com-
plementary tool in detecting CTEPH [17]. Another group
has reported that CPET is able to differentiate CTEPH
from PAH [23]. There are specific patterns leading to the
suspicion of pulmonary vascular abnormalities [17].
Mean pulmonary artery pressure of the patients with
confirmed CTEPH was 36 ± 11 mmHg. Three patients
showed moderate to severe PH. Three patients showed an
mPAP < 25 mmHg but a relevant increase of PAP under
exercise conditions. In these patients PAWP was normal
at rest and under exercise, so it was not considered that
exercise induced PH is due to left heart diastolic dys-
function. Identification of patients with imaging findingssuggesting CTEPH and normal resting hemodynamics but
an increase under exercise conditions is relevant, because
such patients may present as symptomatic as CTEPH
patients. Drastic clinical improvement is seen in these
patients following PEA [9,17].
A diagnostic and follow-up program such as the one
described is intended for early diagnosis and might lead
to detection of CTEPH before hemodynamics become
severely disturbed.
The four subjects definitively diagnosed after six months
had been symptomatic at visit one. Echocardiography and
CPET led to the suspicion of PH and a complete clinical
evaluation had been recommended at this time. Although
our program led to the diagnosis of CTEPH after both the
three and six months and did not detect further CTEPH
cases at the 12-months follow-up, it cannot be concluded
that a one year follow-up is sufficient for the detection of
CTEPH. A “honey-moon” period after acute PE with a
subsequent development of CTEPH is well described
[32]. It is unclear if asymptomatic patients in this
formerly reported cohort would have been detected
with a structured follow-up program. This program is
ongoing with planned follow-up telephone calls after
two and three years in order to detect patients with
slowly developing CTEPH.
Overall this registry study has several limitations:
First, reported data originates from a single center.
Second, due to the design of this study data from a
control cohort has not been reported. It is also rele-
vant to note that the sample size is relatively small.
The questionnaire used in this study was also newly
developed and therefore should be made more specific
and validated towards detection of CTEPH. However,
the robustness of the data as shown by right heart
catheterization and imaging in all subjects following
diagnosis of CTEPH and CTPVD suggests that this
program could be a practical approach for diagnosis of
CTEPH after acute PE.
Further advantages of a structured follow-up program
could be to detect and avoid premature termination of
anticoagulation therapies as well as detection of comor-
bidities such as cancer and cardiovascular diseases which
seems to be relevant in consideration of the observed
long-term mortality after acute pulmonary embolism.
Conclusions
The symptom-related follow-up program which is based
on a telephone-monitoring and a 5-item-questionnaire can
be used to detect patients with CTEPH by further clinical
evaluation of symptomatic patients. CPET may serve as a
complementary diagnostic tool. Telephone monitoring and
CPET seem to be effective and should be included in a
pulmonary embolism follow-up-program used for early
detection of CTEPH.
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